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Inspired by recent suggestions that the Alzheimer’s amyloid β peptide (Aβ) can insert into cell
membranes and form harmful ion channels, we model insertion of the 40 and 42 residue forms
of the peptide into cell membranes using a Monte Carlo code which is specific at the amino
acid level. We examine insertion of the regular Aβ peptide as well as mutants causing familial
Alzheimer’s disease, and find that all but one of the mutants change the insertion behavior by
causing the peptide to spend more simulation steps in only one leaflet of the bilayer. We also find
that Aβ42, because of the extra hydrophobic residues relative to Aβ40, is more likely to adopt this
conformation than Aβ40 in both wild-type and mutant forms. We argue qualitatively why these
effects happen. Here, we present our results and develop the hypothesis that this partial insertion
increases the probability of harmful channel formation. This hypothesis can partly explain why
these mutations are neurotoxic simply due to peptide insertion behavior. We further apply this
model to various artificial Aβ mutants which have been examined experimentally, and offer testable
experimental predictions contrasting the roles of aggregation and insertion with regard to toxicity
of Aβ mutants. These can be used through further experiments to test our hypothesis.
I. INTRODUCTION
Scientific and public interest in Alzheimer’s disease has
surged in the last several decades. The reason for this
is simple: with increasing life expectancy, Alzheimer’s
disease has emerged as the most prevalent form of late-
life mental failure in humans (Selkoe, 2001).
Alzheimer’s disease (AD) is a neurodegenerative dis-
ease involving progressive memory impairment, altered
behavior, decline in language function, disordered cog-
nitive function, eventual decline in motor function, and,
finally, death (Selkoe, 2001). In AD, the brain is typ-
ically marked by lesions (Selkoe, 2001), neuronal dam-
age, and vascular damage (Durell et al., 1994). These le-
sions are typically associated with extracellular plaques,
called amyloid plaques, and intraneuronal fibrillar tan-
gles (Durell et al., 1994; Selkoe, 2001). The tangles are
composed of a protein called Tau and are called Tau
tangles, while the extracellular plaques are largely com-
posed of amyloid β peptide (Aβ) in 40 and 42 residue
forms (Selkoe, 2001) (denoted Aβ40 and Aβ42, respec-
tively). These insoluble amyloid plaques composed of
Aβ are considered a hallmark of AD. However, they
are not specific to AD (Dickson and Vickers, 2001) and
have been observed in older patients free from AD symp-
toms (Jarrett et al., 1993). It has been pointed out that
correlations between amyloid plaque density and severity
of dementia are weak, while there are stronger correla-
tions between soluble Aβ levels and severity of demen-
tia (Walsh et al., 2002). This is one reason for the sugges-
tion that oligomers of Aβ may be more important to toxi-
city than large insoluble aggregates or plaques. Evidence
for this idea has been provided in vivo (Walsh et al.,
2002) and in vitro (Hartley et al., 1999; Lambert et al.,
1998).
One mechanism by which oligomers can damage cells
is formation of pores or ion channels through the cell
membrane. Early work in this area showed that Aβ can
insert into model planar lipid bilayers and allow a calcium
current upon insertion, and further that these channels
can be blocked (Arispe et al., 1993), suggesting that the
calcium current is really due to channel formation, not
just bilayer permeabilization by the peptide. Theoret-
ical modeling based on predicted secondary structures
for membrane-bound Aβ has suggested that the Aβ pep-
tide can form channels with four or six Aβ subunits in
each leaflet of the bilayer (for a total of 8 or 12 per
channel) (Durell et al., 1994). More recent work has
been done using atomic force microscopy (AFM) to look
at the structure of Aβ inserted in planar lipid bilayers
and has found what appear to be channels consisting of
four or six visible subunits around a central pore, consis-
tent with the theoretical picture described above. The
monomers oligomerize after insertion into the bilayer.
Furthermore, in the presence of these oligomers, current
can flow (Lin et al., 2001). Lin et al. (2001) also show
that, under similar conditions, Aβ42 induces neuritic de-
generation and death in cell culture and that this toxicity
is calcium-dependent and blocked by zinc. Imaging work
by another group has also shown that Aβ40 oligomers
with the E22G mutation (where glutamate (E) at residue
22 is replaced with glycine (G)), which causes a form of
familial AD, can form pore-like structures (Lashuel et al.,
2002). These pore-like structures actually could be in-
termediates which, when not membrane bound, build up
into the amyloid plaques observed in the brain of AD
patients (Lashuel et al., 2002).
Based on these suggestions, and the observation of
2Lin et al. (2001) that oligomers in the membrane form
after insertion of monomers, we model insertion of the
Aβ peptide into the cell membrane. We first examine
the regular Aβ40 and Aβ42 peptides, then the 40 and 42
residue versions of all of the mutations in the Aβ pep-
tide that are known to cause familial AD (FAD) and
reduce the average age of onset for the disease compared
to people with sporadic AD (Selkoe, 2001). We believe
FAD mutants provide a tool for assessing proposed tox-
icity mechanisms, in that the biological toxicity mecha-
nism should explain why these mutants cause FAD. Our
reasoning in looking at these mutants is that if the in-
sertion behavior of the FAD mutant peptides is differ-
ent, this could make a difference in the prevalence of
oligomers in the membrane and thus have an effect on
toxicity, if membrane-associated oligomers are indeed im-
portant for toxicity in vivo. While some earlier modeling
work has dealt with the structure of Aβ40 in a lipid bi-
layer (Pellegrini-Calace et al., 2003), we believe this work
is the first to compare insertion of FAD mutants.
This system is modeled using a Monte Carlo (MC) code
which has been developed to study insertion behavior of
peptides into lipid bilayers. This model, which is specific
at the amino acid level, allows us to simulate larger pep-
tides and longer timescales than traditional molecular dy-
namics simulation studies. The configurational steps are
sufficiently small that it has been used successfully to sug-
gest insertion mechanisms, as well as to describe insertion
conformations for some peptides (Maddox and Longo,
2002a,b). Here, we find that in all cases the peptide in-
serts relatively easily. However, we find differences in the
conformations the peptide adopts once inserted. These
differences in the prevalence of conformations are our cen-
tral result. Relative to the normal Aβ peptide, most of
the FAD mutant peptides are more likely to insert only
partially in the bilayer. We point out similarities be-
tween this partially inserted conformation and the pre-
dicted channel structures (Durell et al., 1994). Thus we
suggest that FAD mutants may, in this way, facilitate
formation of harmful channels. Moreover, the Aβ42 pep-
tide, with additional hydrophobic residues, has a greater
tendency than Aβ40 to hang up in this conformation, and
this may correlate with the increased toxicity of Aβ42.
II. INTRODUCTION TO THE MODEL AND METHOD
A. Model energy function
The Monte Carlo model used here has been de-
scribed in detail in an earlier publication in this jour-
nal (Maddox and Longo, 2002a). Accordingly, we give a
brief overview of the essentials here and direct the inter-
ested reader to the earlier reference for greater detail.
The model follows previous work from the past
decade, most notably and closely that of Milik
and Skolnick (Milik and Skolnick, 1992, 1993) and
Baumgaertner(Baumgaertner, 1996). Each amino acid
FIG. 1 Functions characterizing bilayer properties.
The lipid bilayer is described by three functions, w(z) for
the fractional water content, p(z) for the polarity, and y(z)
for the hydrophobicity. Here the z-axis is perpendicular to
the plane of the bilayer, and the functions (and the bilayer)
are symmetric around z=0.
residue is treated as a sphere of identical 1.5A˚ radius.
There are three contributions to the potential energy
function which are residue independent: 1) Us, which is
a hard core steric interaction preventing residue-residue
overlap; 2) UT , an energy measuring the cost of ro-
tating the peptide planes of successive residues, which
is periodic in the torsional angle φ between successive
residues and has a shallow minimum at φ = 52.1o; and
3) UA, characterizing the energy of distortion of the an-
gle θ between adjacent bonds, with a shallow minimum
at θ = 89.5o.
The lipid bilayer with surrounding water is modeled as
a medium without molecular specificity, but with three
different spatial regions. The bilayer’s normal is taken to
lie along the z-axis, so these regions are invariant in the
x− y plane. The bilayer has overall thickness 2(z0+ zh),
where z0 is the length of the acyl chains of a given leaflet,
and zh is the width of the headgroup region. We have
used zh =4.5A˚ and z0 =13.5A˚. We have also tried dif-
ferent chain lengths z0 but we do not present the results
here as they were not significantly different except for re-
ductions in the amount of the transbilayer conformation
of the inserted peptide when the membrane is sufficiently
thick, as we discuss in the results section.
The water-lipid medium is characterized by three di-
mensionless functions, two of which couple linearly to
residue specific parameters we discuss in the next para-
graph. These functions are (as shown in Fig. 1):
1) w(z), which measures the fractional water content;
this is modeled as a step function with exponentially
rounded edges (decay length of 2A˚) that is zero in the
hydrophobic acyl chains, one in the water region, and
varies smoothly through the head region.
2) A polarity function p(z), also exponentially rounded
3with the same decay length, and chosen to be one in the
lipid head regions and water while falling to some small
value 1−fq (where fq, the polarity factor, determines the
polarity of the tail region, with larger fq corresponding to
a less polar tail region) after approximately one residue
diameter into the tail region.
3) A hydrophobicity function y(z), which is the sum of
two exponentially rounded step functions: one which is
zero in the water region and saturates in the head region,
proportional to the total gain of hydrophobic energy in
the head region, and a second which saturates in the
tail region after approximately one residue diameter and
accounts for the hydrophobic energy gained for residues
penetrating the acyl tail region.
The water content w(z) couples linearly to the external
hydrogen bonding energy of each residue, which is residue
independent in form. The net hydrogen bonding energy
is taken as UH given by a sum over residues i
UH =
∑
i
(w(zi)H0 + (1 − w(zi))Hint(i)) (1)
where H0 = −6.12 kcal/mol is the transfer energy of
an unbonded peptide group to water and Hint(i) the in-
ternal hydrogen bonding energy associated with α-helix
formation given by
Hint(i) =
H0
4
∑
n=−4,−3,3,4
VH(|~rn+i − ~ri|) . (2)
VH is a nearly hard-core function of the separation be-
tween residue i and the potential helical hydrogen bond-
ing partners along the peptide chain, as proposed by Mi-
lik and Skolnick (Milik and Skolnick, 1993).
Residue specificity is included in two energies associ-
ated with polarity and hydrophobicity. First, a poten-
tial energy term UQ =
∑
i q0(i)p(zi) is included, where
q0(i) is the residue-specific polar energy associated with
charged or partially charged functional groups. Second,
a hydrophobic energy UB =
∑
i B(i) is included, where
B(i) = y(zi)b0(i)+(1−y(zi))
b1(i)
4
∑
n=−4,−3,3,4
VH(|~rn+i−~ri|) .
(3)
Here, b0(i) is residue specific and measures the water-
to-alkane Gibbs hydrophobic transfer energy for residue
i, and b1(i) is the maximum reduction in hydrophobic
energy due to helical folding. b0(i) is taken to be pro-
portional to the stochastic accessible area of the residue.
The helical-folding related term derives from the loss of
accessible surface area associated with helix formation.
Values for q0(i), b0(i), and b1(i) for all residues are tabu-
lated in the previous work (Maddox and Longo, 2002a).
Note that because the model treats the lipids and water
only as media, the hydrophobic energy must be included
explicitly in our model energy function.
Because of the way the hydrophobic and hydrogen
bonding energies are calculated – simply based on lo-
cal helicity – the simulation is biased toward alpha
helices, as beta structure involves longer range inter-
actions and is not taken into account by the model.
Therefore, the model will not accurately describe in-
sertion behavior of any peptide that inserts while in a
conformation rich in beta structure. Fortunately, the
monomeric Aβ peptide is predicted, based on secondary
structure, to be alpha helical between residues 15 and 40
or 42 (Durell et al., 1994; Pellegrini-Calace et al., 2003)
when membrane-bound. Experimental NMR work in
aqueous sodium dodecyl sulfate micelles, which to some
extent resemble a water-membrane medium, confirms
this for Aβ40 (Coles et al, 1998). Thus the model’s bias
away from beta structure should not play a significant
role here. Indeed, we find that the region mentioned
above inserts into the membrane in a largely helical struc-
ture, as described below.
Our total energy is then taken as the sum U = US +
UT + UA + UB + UQ + UH . All of our modeling pre-
sented below is done at pH 7.0 with temperature 305
K, and uses a polarity factor fq = 0.85, corresponding
to a polarity between that of octanol and hexadecane.
The choice of this value is based on experimental stud-
ies (Griffith et al., 1974; Roseman, 1988) and earlier sim-
ulation work (Maddox and Longo, 2002a).
B. Monte Carlo simulation details
The simulation method is the canonical MC method.
We use periodic boundary conditions in all three direc-
tions, and in the case where the peptide runs across the
boundary, interactions are calculated using the minimum
separation between the two residues in question (the min-
imum image convention). New peptide conformations are
generated using three different sorts of moves:
1) Peptide translation: The whole peptide is randomly
translated a small distance (between 0 and 0.2 A˚) along
each Cartesian axis.
2) Spike move (two sorts): (a) For an end residue, the
virtual bond connecting it to the chain is rotated slightly,
first in the x-y plane, and then in the y-z plane. The
angle of rotation is random, between 0o and 20o. (b)
For a central residue, the residue is rotated a random
(between 0o and 20o) amount around an axis joining the
centers of its nearest neighbors, while keeping all virtual
bond lengths fixed.
3) Slide move: A random virtual bond is selected and
all residues on one side (selected randomly, either up or
down the chain) of it are moved a small, random amount
(between 0 and 0.2 A˚), while remaining fixed relative to
one another. The move leaves the initial virtual bond
the same length but rotated relative to the residues it
connects.
One MC step consists of one modification of each
type 1, 2, and 3, where the choice of residue is random
for (2) and (3). Modifications are accepted or rejected
with a probability given by the usual Boltzmann factor
p = e−
∆U
RT so that favorable moves, with a negative ∆U ,
4are always accepted, and some unfavorable moves are ac-
cepted.
In our work, we wanted to capture insertion behavior
without biasing results by initial peptide conformations.
We have done two groups of simulations to accomplish
this. First, we have started the peptide outside the bi-
layer in the aqueous phase in a random conformation.
Second, we have started the peptide in an initially heli-
cal, fully inserted conformation.
MC simulations can be used to investigate non-
equilibrium properties (e.g. insertion mechanisms) or
equilibrium properties (e.g. inserted conformations) of
a system. When these simulations are used to study
equilibrium properties, it is important to ensure that the
system has fully equilibrated before data collection be-
gins. If this is not done carefully, one consequence is
that the so-called equilibrium state might depend on the
initial conditions. To establish an appropriate period of
equibration, we monitored the average energy of the pep-
tide as a function of simulation steps. As the peptide
equilibrates (reaching its energetically preferred confor-
mation(s)), the average energy decreases from an initially
higher value. Thus we can get a reasonable idea how
many simulation steps it takes for this to happen simply
by plotting energy versus step number.
Using this method, we find that for insertion from an
initial conformation outside the bilayer, a 30 million step
equilibration period is usually sufficient, while for an ini-
tially inserted and helical conformation, 30 million steps
is always sufficient. Although both initial conformations
eventually produce the same equilibrated state, the in-
serted helical conformation converges more rapidly and
is used, with an equilibration period of 50 million steps,
in all our simulations (unless otherwise noted).
As a further test that our equilibration period is suf-
ficient, we have also used conformations from peptides
at the end of an entire simulation run as starting points
for new simulations, and the results at the end of both
simulations are within our error bars of one another.
It is worth pointing out that no equilibration would
be required if the insertion mechanism is being studied.
However, in this work, we find that in every case insertion
is fairly easy, as we discuss in the results section. Thus
we focus on peptide conformations at equilibrium.
C. Data collection
Every MC simulation run employs a unique set of ran-
dom numbers, resulting in a slightly different result each
trial (similar to the way in which no two experimental
measurements are identical). More accurate data are
therefore generated by averaging multiple runs. Here, we
have run a minimum of 10 trials for every peptide: five
beginning in initially helical and inserted conformations,
and five with initially random conformations outside the
bilayer. Following equilibration (discussed above), data
is collected for 50 million steps. In this paper we report
the results of the initially inserted conformations, thus
our results are averaged over a minimum of five such tri-
als. However, as we will discuss in the appendix on data
analysis, in some cases we use more trials.
III. RESULTS
A. Overview
Overall, we simply input the sequence of Aβ40 and
Aβ42 and various mutants and run the simulations. As
discussed above, we do multiple trials for each peptide
and average the results. What we find, briefly, is that the
peptides all insert relatively easily into the bilayer if they
begin initially outside the bilayer, and we do not find that
the FAD mutations significantly effect this ease of inser-
tion. However, we find that the mutations do influence
the conformation the peptide adopts once inserted into
the bilayer. Therefore, our focus in this work is not on
details of how the peptide inserts, though we believe it is
likely that insertion proceeds via one of the two main in-
sertion mechanisms described previously (Baumgaertner,
1996; Maddox and Longo, 2002a).
One of our fundamental results is that the peptide
appears to exhibit multiple possible inserted conforma-
tions which have nearly the same energies, thus allow-
ing the peptide to switch between conformations of-
ten in the course of a simulation. We have previ-
ously described such behavior as conformational parti-
tioning (Maddox and Longo, 2002b). We find that that
the Aβ peptide and its mutants can always adopt the
same, small set of conformations. However, the muta-
tions alter the number of MC steps the peptide spends
in each of these conformations (which, in a real system,
would correspond to the number of inserted peptides in
each conformation). These conformations are shown in
Fig. 2 and Fig. 3.
Essentially, it is quite easy to distinguish three confor-
mations: the first has the last several residues anchored in
the lower head region. We call this conformation “trans-
bilayer”. The second conformation is similar, but usu-
ally much more prevalent since the last residues are hy-
drophobic and prefer to remain in the tail region. This is
especially true in the case of Aβ42. In this conformation,
the essential difference is that the tail of the peptide is
not anchored and thus is fairly floppy and able to change
the angle it makes with the z-axis easily. We call this
conformation “fully inserted”. The third conformation is
different in that in the first two, only residues 1-15 or so
remain in the upper lipid head region, while in the third
conformation, the polar residues 22-23 and/or 26-28 also
remain in the upper head region (along with some of their
neighbors), where there is still some water content. As a
result, the C terminus (residue 40 or 42) does not stick
down into the lipid tail region nearly as far as in the other
two conformations. We call this conformation “partially
inserted”. In this case all, or almost all, of the peptide is
5FIG. 2 Primary inserted conformations of the Aβ pep-
tide. We find that in every case, the inserted peptides can
adopt essentially three different conformations. Mutations
appear to alter the percentage of steps the peptide spends in
each conformation but do not fundamentally change the con-
formations. (a) Transbilayer: The peptide inserts with the
last several residues near the C-terminus in the lower lipid
head region; the portion crossing the bilayer is roughly heli-
cal. (b) Fully Inserted: Just like (a), except the last several
residues are not anchored in the lower head region, meaning
that the conformation is fairly flexible. (c) Partially Inserted:
Like (b), except now much more of the peptide is tethered to
the upper head region by the polar residues 22-23 and 26-28,
whereas before only residues 1-15 or so were in the upper head
region. The conformations shown are for Aβ40, but Aβ42 has
similar conformations with two additional residues (isoleucine
and alanine) the the C-terminus.
FIG. 3 Sub-configurations associated with locations of
the polar residues.We can further break up the partially
inserted conformation, (c) from Fig. 2, into two conforma-
tions: (a) a conformation where only residues 22-23 remain
in the upper head region, and (b) a conformation where both
residues 22-23 and 26-28 remain in the upper head region.
only in the upper leaflet of the bilayer.
This third, partially inserted conformation can be di-
vided into two conformations simply by distinguishing
whether it is residues 22-23 that remain in the upper
head region, or also residues 26-28. This separation of
conformations is shown in Fig. 3. Some of our analysis
is done grouping these together, and some by separating
them, as we will discuss below.
Briefly, we find that when the FAD mutations have an
effect on the insertion behavior, it is usually by causing
the mutant peptides to favor the partially inserted con-
formation more than wild-type. The E22G mutant is an
exception, as it essentially eliminates this conformation.
We refer the reader to the appendix for detailed discus-
FIG. 4 Number of steps at each z-coordinate (vertical
axis is z-axis; darker means more steps) plotted ver-
sus residue number (sequence shown), from 1-40 for Aβ40,
(a), and from 1-42 for Aβ42, (b). Note that on residue 30,
there appear three dark regions, corresponding to three peaks,
while residues 26 and 28, for example, have four peaks. This
result is important for our data analysis. Note also that the
transbilayer conformation for Aβ42 is less common than for
Aβ40 (compare the darkness, or number of steps, of the lowest
peak on residue 40 for Aβ40 and Aβ42. The sequence of Aβ
has polar residues in gray, hydrophobic residues underlined,
and charged residues with charges indicated.
sion of our data analysis procedure. Overall, however, the
basic output of the simulation is the number of steps, or
percentage of steps, each residue in the peptide spends at
each z-coordinate. We can plot this for all residues (Fig.
4) or particular residues (Figs. 5-7). With some analysis
of these (the data analysis is explained in the appendix)
we are able to get accurate measurements in increases or
decreases in the number of steps the peptide spends in a
given conformation, relative to wild-type. We are able to
do this whether we choose to separate the peptide’s con-
formations into three or four groups. Results obtained
using these methods are presented in Table 1 and Table
2.
B. Normal Aβ peptide insertion
As detailed in the appendix, some results for Aβ40,
Aβ42, and various mutants, are shown in Fig. 5, 6,
and 7. We have also extracted the number of steps in
each conformation and present these (measured as per-
centages of total steps) in Table 1, along with standard
deviations. As we discuss in the appendix, the percent-
ages for conformations (b) and (c) are not completely
accurate as absolute measures of the number of steps in
those conformations, but the change relative to wild-type
is accurate.
It is important to note that there is a fundamental dif-
ference between Aβ40 and Aβ42. While both can adopt
all the conformations of Fig. 2, Aβ42 spends many fewer
steps in conformation (a). This is because the last two
6Three peak analysis Four peak analysis
Peptide form Onset % trans. % fully ins. % partially ins. ∆% upper(a) ∆% upper(b)
WT Aβ40 72.8 15.6 +/- 3.8 48 +/- 5.2 36.3 +/- 6.8
Aβ42 2.1 +/- 0.5 58.5 +/- 5.6 39.4 +/- 5.8
A21G Aβ40 52 17.6 +/- 3.0 48.3 +/- 6.8 34.1 +/- 8.0 0.5 +/- 1.8 2.9 +/- 8.4
Aβ42 1.9 +/- 0.7 44.4 +/- 5.4 53.7 +/- 5.4 -2.8 +/- 3.2 14.8 +/- 6.9
E22G Aβ40 57 27.4 +/- 7.5 67.4 +/- 7.0 5.13 +/- 7.0 -11.8 +/- 1.6 -13.2 +/- 6.2
Aβ42 2.3 +/- 1.7 94.8 +/- 7.0 1.29 +/- 1.0 -16.8 +/- 3.7 -9.6 +/- 5.6
E22Q Aβ40 ? 13.6 +/- 4.6 43.6 +/- 5.5 42.8 +/- 5.5 6.4 +/- 3.5 2.8 +/- 11.0
Aβ42 2.0 +/- 0.3 55.8 +/- 6.9 42.2 +/- 7.0 4.5 +/- 3.4 -1.8 +/- 8.7
E22K Aβ40 ? 15.5 +/- 9.6 37.9 +/- 5.2 46.6 +/- 6.0 9.9 +/- 2.3 2.2 +/- 10.0
Aβ42 1.3 +/- 0.8 34.2 +/- 10.5 64.5 +/- 9.4 9.4 +/- 8.0 14.6 +/- 17.1
D22N Aβ40 69 13.1 +/- 9.2 30.0 +/- 8.8 56.8 +/- 10.2 8.6 +/- 7.2 10.8 +/- 16.2
Aβ42 1.2 +/- 0.5 41.1 +/- 16.3 57.7 +/- 16.7 0.6 +/- 5.8 16.0 +/- 11.4
TABLE I Frequency of each conformation for native and FAD Aβ peptides. Ages of onset (where
known) (Grabowski et al., 2001; Li et al., 2002; Nilsberth et al., 2001; Roks et al., 2000) and simulation results: percentage
transbilayer, percentages in the fully inserted (Fig. 2(b)) and partially inserted (Fig. 2(c)) conformations as calculated from
the three peak analysis on residue 30. The last two columns measure the change in percentage of the conformations of Fig.
3(a) and 3(b) relative to wild-type (from the four peak analysis). For each mutation, one row represents Aβ40 and the next
Aβ42. Onset age is not specific to the 40- or 42- residue forms. Here, the only consistent trend that we find is that most of the
FAD mutants, with the exception of E22G, appear to increase the percentage of the partially inserted conformation relative
to wild-type. This appears to be true for both Aβ40 and Aβ42. By way of comparison, the FAD mutations increase fibrillar
aggregation of Aβ42 in vitro in every case except the A21G mutant (Murakami et al., 2002) and increase soluble Aβ levels in
every case but the E22G mutant (Lashuel et al., 2002; Nilsberth et al., 2001). To improve statistics, wild-type Aβ40 results
are the average of 25 trials rather than the usual 5; wt Aβ42 are the average of 20; A21G Aβ40 20 trials; A21G Aβ42 10 trials,
and Aβ42 E22Q and D23N 10 trials each. All the rest are 5 trials, as described in the data analysis section.
residues of Aβ42 add significantly to the hydrophobicity
of the C-terminus (see sequence in Fig. 4), as both are
nonpolar and isoleucine is strongly hydrophobic. One
might well ask, however, why Aβ40 has its last three
residues in the lower head region at all, especially the
final two valines, which are nonpolar and strongly hy-
drophobic. To understand this effect, it is worth noting
that in this conformation, the transbilayer helix begins
after, or around, residue 16, lysine, which is the final
charged and polar residue prior to a number of nonpolar,
hydrophobic residues, beginning with leucine. To remove
residues 39 and 40 from the lower head region would re-
quire either the peptide to insert at a more shallow angle
so that these residues do not make contact with the lower
head region, or putting a kink in the helix (as in Fig.
2(b)) so that they do not make contact. In the first case,
changing the insertion angle would move lysine, and pos-
sibly residues after it (it is immediately followed by va-
line), into the upper head region where there is still some
water. This would be costly energetically. So is putting
a kink into the helix. Thus we believe that, in the case
of Aβ40, the energy cost of either putting a kink in the
helix, or imbedding K16 and V17 in the upper head re-
gion, is comparable to the energy cost of imbedding V39
and V40 in the lower head region, thus the conforma-
tion 2(a) does occasionally happen. On the other hand,
for Aβ42, the additional I41 makes this conformation so
costly that it almost never happens. This reduction in
the transmembrane conformation results in an increase
in the prevalence of the other two conformations relative
to Aβ40 which, if correct, could help explain why Aβ42
is typically more toxic.
It is probably important to point out that our results
do not necessarily mean Aβ40 would be transmembrane
biologically. We have tried making the bilayer slightly
thicker (by 5A˚) and the transbilayer conformation essen-
tially disappears. This means the transmembrane inser-
tion is due to the limited space between head regions,
as we argued above. Biologically, the membrane could
be slightly thicker than our model, or the peptide might
cause a small bulge in the membrane to accomodate a
fully inserted, rather than transbilayer, conformation.
So, although the simulation does produce this transbi-
layer conformation, we have no reason to believe that
this conformation would be distinct from the fully in-
serted conformation in biological systems. On the other
hand, this configuration does exist in our model. Here,
it is the reduction in the prevalence of this configuration
that makes the other two configurations more prevalent
for Aβ42 than Aβ40.
C. FAD Aβ peptide insertion
1. FAD mutations
There are a number of known FAD mutations, in-
cluding some involving Aβ (as well as others involved
7Three peak analysis Four peak analysis
Peptide form % trans. % fully ins. % partially ins. ∆% upper(a) ∆% upper(b)
WT Aβ40 15.6 +/- 3.8 48 +/- 5.2 36.3 +/- 6.8
Aβ42 2.1 +/- 0.5 58.5 +/- 5.6 39.4 +/- 5.8
E22QD23N Aβ40 15.5 +/- 5.0 30.0 +/- 6.4 54.6 +/- 6.9 4.4 +/- 6.3 13.9 +/- 16.2
Aβ42 0.9 +/- 0.7 24.6 +/- 11.4 74.4 +/- 11.4 4.0 +/- 10.5 30.9 +/- 19.0
E22A Aβ40 23.1 +/- 7.6 71.7 +/- 7.1 5.2 +/- 0.7 -10.8 +/- 2.3 -13.3 +/- 6.3
Aβ42 2.0 +/- 0.4 85.6 +/- 2.1 12.4 +/- 2.0 -13.8 +/- 7.0 -11.4 +/- 4.2
E22D Aβ40 22.9 +/- 8.9 64.9 +/- 7.6 12.2 +/- 2.0 -3.9 +/- 2.6 -13.1 +/- 6.2
Aβ42 1.9 +/- 1.1 62.9 +/- 6.6 35.2 +/- 6.6 -5.9 +/- 3.4 -0.4 +/- 10.7
A2S Aβ40 17.6 +/- 9.1 49.3 +/- 6.4 33.1 +/- 5.0 -1.2 +/- 9.9 –3.2 +/- 9.7
Aβ42 2.2 +/- 1.3 60.4 +/- 3.4 37.4 +/- 3.3 2.4 +/- 3.3 -5.3 +/- 8.7
F19S Aβ40 1.6 +/- 2.4 5.3 +/- 4.4 93.1 +/- 4.9 4.9 +/- 10.3 57.9 +/- 16.1
Aβ42 0.1 +/- 0.1 10.8 +/- 5.2 89.1 +/- 5.2 7.8 +/- 13.6 43.6 +/- 14.9
I32S Aβ40 14.2 +/- 7.0 34.7 +/- 8.7 51.1 +/- 10.7 -1.7 +/- 3.2 17.0 +/- 12.6
Aβ42 1.5 +/- 0.7 49.5 +/- 13.9 49.1 +/- 14.1 -1.1 +/- 4.5 10.2 +/- 11.5
I32V Aβ40 16.0 +/- 3.9 58.8 +/- 2.8 25.3 +/- 1.3 4.4 +/- 1.6 -10.8 +/- 6.8
Aβ42 2.5 +/- 1.2 63.2 +/- 2.1 34.4 +/- 2.0 -0.1 +/- 3.7 -5.7 +/- 5.6
V36E Aβ40 83.0 +/- 13.9 10.6 +/- 9.3 6.4 +/- 6.2 -12.7 +/- 3.0 -5.3 +/- 13.3
Aβ42 16.7 +/- 11.9 36.2 +/- 19.5 47.1 +/- 10.5 1.6 +/- 5.1 5.6 +/- 11.8
H6R Aβ40 17.3 +/- 4.8 47.7 +/- 7.7 35.0 +/- 8.4 2.2 +/- 2.5 -1.2 +/- 8.8
Aβ42 2.0 +/- 0.6 52.9 +/- 8.2 45.1 +/- 8.4 1.8 +/- 3.7 2.5 +/- 7.3
TABLE II Frequency of each conformation for artificial Aβ mutants. Shown are results for artificial Aβ mutants
mentioned in the literature: percentage transbilayer, percentages in the fully inserted (Fig. 2(b)) and partially inserted (Fig.
2(c)) conformations as calculated from the three peak analysis on residue 30. The last two columns measure the change in
percentage of the conformations of Fig. 3(a) and 3(b) relative to wild-type (from the four peak analysis). The Aβ40 E22QD23N
mutant is more toxic to HCSM cells than either mutant alone (Van Nostrand et al., 2001), while the E22D mutant of Aβ40 is not
toxic to HCSM cells and the E22A mutant is (Melchor et al., 2000). The A2S, F19S, I32V, I32S, and V36E mutants are known
to reduce aggregation of Aβ42 (Wurth et al., 2002), and the H6R mutant has been suggested as an FAD mutant (Janssen et al.,
2003).
in other aspects of the disease including Aβ produc-
tion). These are named by the populations they were first
found in and include Flemish (A21G); Arctic (E22G);
and Iowa (D23N) (Murakami et al., 2002). Murakami
et al. also include Dutch (E22Q) and Italian (E22K)
but there is some dispute about whether these are prop-
erly to be considered AD mutations (Melchor et al., 2000;
Nilsberth et al., 2001; Wattendorff et al., 1995). To un-
derstand this, it is important to note that AD is of-
ten accompanied by cerebral amyloid angiopathy (CAA),
deposition of Aβ in blood vessels of the brain poten-
tially leading to vessel rupture and stroke, especially in
FAD cases (Murakami et al., 2002). Wattendorff et al.
(1995) point out that classic Alzheimer’s plaques are
rarely found in the Dutch CAA case and dementia and
death are due to cerebral hemorrhage involving damage
to blood vessels, as is also the case in the Italian E22K
mutant (Melchor et al., 2000). But the fact that AD also
involves amyloid angiopathy leaves open the possibility
that the Dutch and Italian forms are vascular forms of
AD (Wattendorff et al., 1995).
Here, we set aside the issue of whether or not the Dutch
and Italian Aβ mutations are actually AD mutations or
whether they should be regarded as something different
and simply model insertion of these peptides into cell
membranes. It is known that even the Dutch E22Q and
Italian E22K mutant peptides interact with cell surfaces
of cerebralvascular smooth muscle cells and cause cell
death in vitro (Melchor et al., 2000). Thus, it is conceiv-
able that the mechanism may be similar to that described
by Lin et al. (Lin et al., 2001) and the type of cells being
damaged may simply be different – either cerebralvas-
cular smooth muscle cells (Melchor et al., 2000) or brain
pericytes (Verbeek et al., 1997) rather than neurons. For
simplicity, we will call all of these FAD mutations.
It is also important to note that these Aβ mutations
are autosomal dominant (Nilsberth et al., 2001) and, in
addition to lowering the age of onset for AD compared
to sporadic cases, cause AD in all subjects with the mu-
tations who live long enough. Many of these mutations
also lead to increased Aβ levels, but that cannot be the
sole cause, as at least the Arctic mutation (Lashuel et al.,
2002) leads to decreased levels. The cause of disease also
cannot be simply due to increased propensity to form
fibrils or aggregates, because at least the Flemish muta-
tion does not increase fibril formation (Murakami et al.,
8FIG. 5 Binned numbers of steps spent at each z-
coordinate for residue 40 of (a) Aβ40 and (b) Aβ42.
Each plot also shows various FAD mutations. It is easily ap-
parent that Aβ42 spends significantly fewer steps in the fully
inserted conformation (leftmost peak) compared to Aβ40. It
is difficult to tell much about the other conformations by look-
ing at this distribution for residue 40, but the prevalence of
these can be extracted from other residues. Note that the
lipid head regions are from z=13.5A˚to z=18A˚(and similarly
for negative z).
2002).
2. FAD mutation results
Results for these mutations are shown in Fig. 5, 6,
and 7, and presented in reduced form in Table 1. We
find that the most consistent difference in results rela-
tive to wild-type, for both Aβ40 and Aβ42, is that four
of the five FAD mutants increase the number of steps
the peptide is in a conformation like that of Fig. 2(c).
The E22G mutant, however, results in a huge decrease
of this conformation. In the other four cases, our results
can easily be understood by considering the changes in
FIG. 6 Binned number of steps spent at each z-
coordinate for (a) residue 30 of Aβ40 and (b) residue
35 of Aβ42. These are the residues we picked which best dis-
tinguish three groups of conformations. The leftmost group
on both, which is very small for Aβ42, is conformations which
appear nearly transbilayer. The middle group is conforma-
tions which are inserted and fairly floppy, as in Fig. 2(b), and
the rightmost group is the partially inserted conformation. It
can be clearly seen that for Aβ40, all of the mutations but
E22G and A21G result in an increase in this last peak relative
to wild-type, and for Aβ42 all of them except E22G do, as
well.
polarity and hydrophobicity the mutations involve.
To understand our results, consider the changes in po-
larity and hydrophobicity the mutations involve. The
polarity and hydrophobicity values used in this model
have been tabulated before (Maddox and Longo, 2002a)
and will not be repeated here, but it is worthwhile to dis-
cuss the mutations briefly. The A21G mutant involves a
decrease in hydrophobicity, hence should cause residue
21 to more strongly prefer to be in the upper head re-
gion and thus result in an increase in the prevalence of
the partially inserted conformation (Fig. 2(c)). This is
what we find, at least for Aβ42 (for Aβ40, the percent-
9FIG. 7 Binned number of steps spent at each z-
coordinate for residue 26 of (a) Aβ40 and (b) Aβ42.
For this residue, there are four apparent peaks, corresponding
to the conformations of Fig. 2(a) and (b), and Fig. 3. For
Aβ42, the transbilayer conformation is so small that there
is no apparent peak. For Aβ40, it is the leftmost peak, fol-
lowed by the fully inserted peak, then the partially inserted
peaks: the peak of Fig. 3(a), and then the peak of 3(b). No-
tice that for both Aβ40 and Aβ42, the FAD mutants increase
the weight of the rightmost conformations (those of Fig. 3)
relative to wild-type, except for the E22G mutant.
age stays about the same). The E22Q mutant involves
a fairly large increase in polarity and slight increase in
hydrophobicity, thus the polarity should dominate and
cause residue 22 to strongly prefer the upper head re-
gion, as we find. The E22K mutant is quite similar, but
involves an even larger increase in polarity, and should
also cause residue 22 to prefer the upper head region,
as we find. And the D23N mutant involves a similar in-
crease in polarity and slight increase in hydrophobicity,
so again the polarity should dominate and increase this
conformation, as we find. On the other hand, the E22G
mutant replaces a polar, charged residue with a neutral,
nonpolar residue and thus residue 22 is now mostly in-
different. This results in the observed huge decrease in
the partially inserted conformation.
On one hand, the different behavior of the E22G mu-
tant could be taken as evidence that there is no consis-
tent change in insertion behavior, and thus suggest that
this may not be the toxicity mechanism, or at least that
oligomerization, not insertion, is important. That is cer-
tainly a possible meaning of these results. However, we
would suggest that the reader compare the conformation
of Fig. 2(c) with the channel structure of Durell et al.
(1994), specifically in Fig. 4 of that paper. Note that
there are two helices predicted, from residues 15-24, run-
ning near the upper head region, and from 25-40 or 25-
42, inserted. In Fig. 2(c), we have a nearly helical region
from around residues 14-24 or 25 that is near the upper
head region, and one from 25-40 which hangs down in-
serted. Thus it resembles the predicted structure more
than either of the other conformations. In the structure
prediction, the part of the chain prior to residue 15 folds
down inside the oligomer and forms a beta-barrel, which
we obviously do not capture here because we do not have
oligomers necessary to stabilize such a structure, and be-
cause the model is not designed to capture beta structure.
With the similarity of Fig. 2(c) to the predicted chan-
nel structure in mind, we form the hypothesis that the
partially inserted conformations (2(c), or 3(a) and (b))
are more likely to form channels, simply because of their
resemblance to the structure of the monomers making up
the channels. Below, in the artificial mutants section, we
test this hypothesis against some experimental data for
artificial Aβ mutants, and present predictions for further
tests.
One might argue that the observed changes in the
prevalence of different conformations are relatively small
and thus would be unlikely to result in a large differ-
ence in the toxicity of the different mutants. However,
these channels consist of eight or twelve monomers. If
one thinks of a large number of monomers inserted in a
bilayer, some will be in each conformation at any given
time, so we can think of the concentration of each con-
formation. Consider, then, the concentration of the con-
formation that can form channels. The time it takes for
twelve monomers within a bilayer to find each other, or
the probability, should scale as c12, where c is this con-
centration. Thus a small difference in the amount in the
proper conformation could make a big difference in the
likelihood of forming channels.
D. Insertion of other mutant Aβ peptides
A variety of other data is available on mutant Aβ pep-
tides. Some reduce aggregation in vitro (Wurth et al.,
2002), some might cause FAD (Janssen et al., 2003),
and some have various effects on cultured cere-
brovascular smooth muscle cells (Melchor et al., 2000;
Van Nostrand et al., 2001). Here, we examine some of
the mutations which have been mentioned in the litera-
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ture as a test of our hypothesis – if it is right, and toxicity
depends in part on the relative prevalence of the partially
inserted conformation, our results ought to correlate with
the experimental toxicity measurements.
First, we address the E22Q,D23N Aβ40 double mu-
tant created by Van Nostrand et al. (2001). This muta-
tion’s effect has been examined on human cerebrovas-
cular smooth muscle cells (HCSM cells) because the
E22Q mutation causes especially pronounced cerebral
amyloid angiopathy and patients with this mutation typ-
ically die of hemorrhage, as discussed above. HCSM
cells are known to degenerate in CAA in a manner that
is associated with Aβ deposition (Melchor et al., 2000).
Van Nostrand et al. (2001) found that the E22Q,D23N
double mutant is even more toxic to HCSM cells than
E22Q or D23N alone. Our idea was that the mecha-
nism for this toxicity also involves insertion of the peptide
and formation of channels, so we modeled this mutant as
well. Results for this mutant are shown in Table 2; we
find that the prevalence of the partially increased confor-
mation does increase relative to wild-type. Relative to
the D23N mutant, which we would predict would be the
more toxic of the E22Q and D23N mutants, we observe
an increase in the partially inserted conformation only
for Aβ42. Again, however, we would argue simply based
on the residue properties that since both the E22Q and
D23N mutants increase preference of those residues for
the upper head region, the double mutant should have
a stronger effect on this than either alone, and thus we
expect that, given better statistics, we would agree with
Van Nostrand et al. (2001) and predict that the double
mutant is more toxic than either alone.
Melchor et al. (2000) have found that an artificial
E22D mutant of Aβ40 does not effect HCSM cells, in con-
trast to biological E22Q and E22K mutants. They also
observed that the Aβ40 E22A mutant is toxic to HCSM
cells. Therefore we model insertion of E22D and find
(Table 2) that the E22D mutant results in a decrease in
the partially inserted conformation (as one would expect
due to the decrease in polarity), especially for Aβ40. The
E22A mutant results in a large decrease in the partially
inserted conformation for both Aβ40 and Aβ42 (again,
as one would expect due to the decrease in polarity).
Thus, based on our hypothesis, we would agree that the
E22D Aβ40 mutant would not be toxic, but disagree that
the E22A mutant would be toxic. This could be taken
as evidence against our hypothesis or evidence that the
toxicity mechanism is different for HCSM cells.
Janssen et al. (2003) recently identified a previously
unknown mutation in the Aβ peptide in two early-onset
AD patients in the same family. This mutation, H6R,
produced ages of onset around 55. We have here tried
this mutation (results in Table 2) and find that it pro-
duces insertion behavior that is within error bars of wild-
type. Given the position of the mutation, this is what we
would expect, as it is within the range of amino acids
(1-14 or more) that are firmly anchored in or near the
upper head region, where there is some water content.
Replacing histidine with arginine, which is even more
polar, does not have a strong effect on this as both try to
remain where there is water, i.e. the surface of the upper
head region. Thus, if toxicity depends only on insertion
conformation, we would suggest that this is indeed not a
FAD mutation. Thus we would suggest testing toxicity of
this mutant in cell culture, particularly as already done
for Aβ42 by Lin et al. (2001).
Some in vitro work has been done to find artificial mu-
tants that can reduce aggregation of Aβ42 (Wurth et al.,
2002). Unfortunately, this has not yet been extended to
include Aβ40. However, we selected some of the point
mutations which are known to reduce aggregation of
Aβ42 and modeled the insertion of these. We tried A2S,
F19S, I32V, I32S, and V36E. Results are shown in Ta-
ble 2. We find that F19S and I32S strongly increase the
prevalence of the partially inserted conformation for both
Aβ40 and Aβ42. For F19S, this is due to the substitu-
tion of polar serine for strongly hydrophobic phenylala-
nine, causing residue 29 to prefer the upper head region;
for I32S, the reason is similar. In this case, the confor-
mation is actually different from normal in that residue
32 also sticks in the upper head region. In contrast, the
I32V mutant does not result in a large change relative
to wild-type, consistent with the relatively small change
between isoleucine and valine. Unsurprisingly, the A2S
mutant makes no change to insertion behavior (residue 2
is firmly in the upper head region, so changing it to po-
lar makes little difference). The V36E mutant, however,
as one might expect, drastically increases the number of
steps that the peptide is transbilayer, as the polar and
charged glutamic acid strongly prefers to be in an envi-
ronment with more water. Thus it decreases the preva-
lence of the partially inserted and fully inserted confor-
mations. Thus we would predict that, if our hypothesis
is correct, F19S and I32S should be the most toxic, I32V
and A2S should be comparable to wild-type, and V36E
might be much less toxic than wild-type. We say might
because this probably depends on the thickness of the
bilayer; if the bilayer is too thick it will probably behave
just like wild-type since the E36 could not reach the lower
head region. Thus a testable experimental prediction of
our hypothesis is that toxicity of these mutants would be
related to their insertion behavior as just described.
We can make a second prediction which is simply based
on the observed insertion behavior of Aβ42. Looking
at the insertion behavior of the Aβ42 versions of the
Wurth et al. mutants, we find that I32V, A2S, and pos-
sibly V36E insert more like natural Aβ42, while F19S,
I32S, and possibly V36E insert differently. The reduc-
tion in aggregation splits the group differently – I32S
aggregates most, then A2S, V36E, and F19S are similar
to one another and intermediate, and I32V aggregates
least (Wurth et al., 2002). So if fibrillar aggregation pri-
marily causes toxicity, experiments looking at toxicity
should see the latter grouping, while if insertion behavior
is of much more importance, toxicity experiments should
see the former grouping.
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IV. DISCUSSION AND CONCLUSIONS
We have here presented work applying a model of pep-
tide insertion to Aβ, a peptide implicated in Alzheimer’s
disease. Specifically, we have examined the effect of FAD
mutations on the peptide’s insertion behavior, with the
idea that any successful hypothetical toxicity mechanism
should be able to explain why FAD mutations are toxic.
Thus if FAD mutants do not affect peptide insertion into,
or oligomerization within, membranes, the ion channel
toxicity mechanism proposed previously (Arispe et al.,
1993; Durell et al., 1994; Lin et al., 2001) is probably not
relevant biologically.
What we find is that the FAD mutations do affect pep-
tide insertion. Four of these five mutations involve an
increase in polarity or decrease in hydrophobicity and
thus cause the peptide to prefer (relative to wild-type) a
conformation where those residues are in the upper lipid
head region (i.e. Fig. 2(c)). It is interesting to note that
a channel structure suggested previously (Durell et al.
(1994), see Fig. 4) has these residues laying along the
surface of the bilayer. Thus we find that four of the five
FAD mutations increase the resemblance to this configu-
ration.
Based on this similarity, we develop the hypothesis
that causing the peptide to hang up in the upper leaflet
(the partially inserted conformation) facilitates forma-
tion of harmful channels. We test this hypothesis on sev-
eral artificial mutations examined in vitro and find that it
can explain the change in toxicity of two and is wrong on
a third. As a further test of our hypothesis, we can offer
some testable predictions. For example, if the hypothesis
is right, we would suggest that the F19S mutant would in-
crease toxicity of Aβ relative to wild-type. Additionally,
there are several mutations known to reduce aggregation
of Aβ42 that we predict would promote the insertion be-
havior that would facilitate channel formation. Thus, it
would be simple to distinguish between the channel for-
mation toxicity mechanism and the aggregation toxicity
mechanism by looking at the toxicity of these mutants.
Even more evidence could be provided by replicating the
work of Lin et al. (2001) but using various FAD mutants
and looking at how these effect the abundance of chan-
nels. Additional information could also be gained from
theoretical work along the lines of that by Durell et al.
(1994) to see what effect these FAD mutants would have
on channel structures.
Overall, this approach of modeling peptide insertion
provides a simple way of making concrete predictions to
distinguish the proposed mechanism of channel formation
from others. The limitation of this approach, however,
is that we can only look at insertion of single peptides,
and not interaction between these. This is fine if forma-
tion of channels depends on having peptides initially in
the correct conformations, which seems reasonable. How-
ever, it is also possible that interaction between inserted
peptides causes them to adopt conformations appropri-
ate for channel formation. If this is the case, then insight
into channel formation would require a more sophisti-
cated model that can include interaction between pep-
tides. Even if this is not the case, including interaction
between peptides will certainly answer the question of
whether FAD mutants affect channel formation in a con-
sistent way much more thoroughly than we are able to do
here. Therefore, this would be a logical continuation of
this work and is something we hope to do in the future.
Even if our hypothesis proves to be wrong, we have
shown that the FAD mutants affect insertion behavior of
the Aβ peptide into lipid bilayers, and provided an un-
derstanding as to why the FAD mutants affect insertion
in the way they do.
In conclusion, our work shows that most FAD muta-
tions have a significant effect on the insertion of the Aβ
peptide in lipid bilayers in this theoretical model, and this
effect can easily be understood by looking at the change
in polarity and hydrophobicity accompanying the muta-
tions. The effect of FAD mutations on insertion has not
been studied previously, and may be significant. Addi-
tionally, we offer a hypothesis based on promoting chan-
nel formation by causing peptides to insert less fully that
can help explain toxicity of Aβ FAD mutants, as well as
several artificial mutants studied in vitro. While this hy-
pothesis is unproven, it is based on the observation that
these peptides do insert into cell membranes and form ion
channels (Lin et al., 2001), and similarities to theoret-
ically predicted channel structures (Durell et al., 1994).
We provide testable predictions based on this hypothesis.
It should be simple for experimentalists to disprove this
hypothesis, if it is false, or to offer additional evidence
for it, if they follow the experimental suggestions we of-
fer above. Additionally, our work suggests the value of
further modeling work to describe the full formation of
these channels, rather than just single-peptide insertion.
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APPENDIX A: Data Analysis
The basic output of the simulation is the binned number
of steps – essentially the frequency with which each residue
is found at each z-coordinate. This can be plotted across all
residues and illustrates, as in Fig. 4, that there are multiple
conformations that the peptide can switch between.
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In terms of data analysis, it is more useful to plot z-
distributions of specific residues which can be used to dis-
tinguish between the conformations described above. For ex-
ample, residue 40 has a well-defined peak in the lower head
region that can be used to distinguish the transbilayer con-
formation from the other conformations. A plot of residue 40
z-distributions for various mutations is shown in Fig. 5.
It is somewhat more difficult to distinguish exactly how
many steps the peptide spends in the fully inserted and par-
tially inserted conformations ((b) and (c) of Fig. 2). To
understand this, it is important to recognize that each confor-
mation results in a peak for a given residue. That is, from Fig.
2, one can easily see that the position of residue 28 has three
significantly different locations depending on which confor-
mation the peptide is in. As it turns out, it also has a fourth,
which is not very different from the third, as can be seen in
Fig. 3. Unfortunately, these peaks tend to overlap with each
other quite significantly – that is, residue 28 can sometimes
have similar locations whether it is in the partially inserted
conformation or the fully inserted conformation. This means
that, to extract the number of steps in a given conformation
from the data, it becomes necessary to fit some function to
the peaks and then calculate the number of steps from that.
To do this, we select residues where the peaks appear to
be particularly well separated. For one, we choose residue 30
(for Aβ40), because at that residue, the peaks corresponding
to the two partially inserted conformations actually overlap –
that is, residue 30 has the same average location no matter
whether it is residues 22-23 alone that are stuck in the upper
head region, or 22-23 and 26-28. This means that we can
extract the weight of conformation (c) from Fig. 2 – the
conformation grouping these two together – by looking at this
residue. For Aβ42, the two peaks of the partially inserted
conformation do not quite overlap for residue 30, but do for
residue 35, so we do the same analysis, but for residue 35. A
plot of the number of steps at each z-value for these residues
is shown in Fig. 6.
To separate the two partially inserted conformations of Fig.
3, we choose three residues that have four peaks that are
the most well-separated (unlike residue 30 or 35, where these
two peaks merge into one). These are residues 26, 28, and
31. Plots of the number of steps at each z-value for different
mutations for one of these residues, residue 26, are shown in
Fig. 7.
Our goal was to find the number of steps in each conforma-
tion. Having chosen the residues where the peaks are the best
separated, it is necessary to find the number of steps under
each peak. Since they overlap, we find that the best way to
do this is to use the least-squares method to find fits to each
peak that best describe the whole function. This is proba-
bly best understood using a concrete example, for which we
choose residue 26.
For residue 26, we know there are four peaks, and, as seen
in Fig. 7, the locations of these are fairly clearly visible. To
fit these peaks, we begin by averaging all of our results for
the wild-type form of Aβ40. We assume that the peaks are
Gaussian. Since the peaks are reasonably well separated, we
assume initially that the center of each Gaussian is at the
maximum. Then, we perform a least-squares fit of the stan-
dard deviation and amplitude of each Gaussian. Particularly,
we perform our fit by looping through the peaks and sug-
gesting changes first to the standard deviation and then to
the amplitude. Each time, we try both increasing and de-
creasing the standard deviation by a specified step size, and
FIG. 8 Binned number of steps spent at each z-
coordinate for residue 26 of (a) Aβ40 and (b) Aβ42,
along with fits used for data analysis. Shown here are
the data for wild-type, compared to fits of Gaussians, as de-
scribed in the data analysis section. The Gaussians appear to
provide fairly good fits and thus we use these in this work to
calculate the number of steps in each conformation.
check whether this improves the quality of the fit. We then
move on to the next peak and do the same thing, then repeat
the process for the amplitude. Then we reduce the step size
and repeat the whole process. We do this until the fit can
no longer be improved by further iterations of the process.
Having done all that, we also then try altering the locations
of the centers of the Gaussians slightly to see if it improves
the fit. Having then selected optimal standard deviations and
center locations, we store those, and assume that the shape
and location of each peak will remain the same for other sim-
ulations, simply the amplitudes will vary. A sample such fit
is shown in Fig. 8. As is apparent from the figure, the fit is
good. Therefore, we concluded that assuming the peaks are
Gaussian is sufficient, at least to get a reasonable estimate of
the number of steps in each conformation.
Having done this, we are able to then perform a four pa-
rameter fit for every other data set for every Aβ40 mutation
data set, simply by fitting the amplitudes while keeping the
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standard deviations and peak locations fixed. We have also
tried allowing the standard deviations to vary when doing
these subsequent fits but this does not substantially improve
the quality of the fit, and it seems reasonable that the shape
of a given peak for a given residue should be constant.
We apply a similar technique to fitting residues 28 and
31, and residue 30, but we fit residue 30 using only three
peaks, and we do the same for Aβ42. Additionally, using this
technique, we are able to calculate standard deviations for a
given peptide or mutant. For example, for the D23N mutant,
where residue 23 is changed from aspartate (D) to asparagine
(N), we perform a fit separately for each of our five MC runs
and calculate the area under each peak. Then, we average the
results over all five trials and calculate the standard deviation.
For the four peak case, it is somewhat difficult to accurately
separate the third and fourth peaks, thus it helps that we are
able to separately perform fits to four peaks on residues 26,
28, and 31. We are thus able to take the apparent change of
steps under each of these three peaks relative to the wild-type
and average over all three residues. This significantly reduces
our error.
There is one more factor which complicates issues. Going
back to our earlier example of the location of residue 28 in
Fig. 2, it appears in very different positions along the z-axis
depending on which conformation the peptide is in. However,
it is also possible to have conformations where residue 28 may,
for example, be quite low, like it is in the transbilayer con-
formation (Fig. 2(a)) but residues 38-40 are not in the lower
leaflet. This effect gets worse the further the residue being
examined is from residue 40, and is apparent in Fig. 6 and 7
as the area under the “transbilayer” peak on those residues is
obviously much larger than the area under the same peak on
residue 40, simply because more conformations look similar
to the transbilayer conformation.
This means that the calculated number of steps under each
peak for residues 26, 28, 30, and 31, while accurate, are not re-
ally to be taken as a measure of how many simulation steps the
peptide spends in each of those conformations. Since the peak
shapes remain constant over the different mutations, however,
these do accurately describe the change relative to the wild-
type. That is, an increase in the prevalence of the conforma-
tion of Fig. 2(c) relative to wild-type for a given mutation is
correct, while the absolute number of steps in that conforma-
tion may not be accurate, except for the conformation of Fig.
2(a), which we can extract accurately from residue 40.
As we discussed above, for many of the peptides we have
studied we have averaged over five trials. However, for some
we have used significantly more trials. Specifically, for wild-
type of Aβ40 and Aβ42, we used more trials, as it was par-
ticularly important to have a good average for those results
since we compare all of our other results to those. For Aβ40
we used 25 trials; Aβ42 we used 20. Additionally, for mutants
with particularly small changes relative to wild-type, or par-
ticularly large standard deviations, we also used more runs.
We did 20 trials for A21G Aβ40; 10 for A21G Aβ42, and 10
each for Aβ42 E22Q and D23N. Of the artificial mutants, we
did 10 trials for Aβ40 and Aβ42 of both I32S and H6R.
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